For families affected by rare genetic skin diseases, hope once meant daily bandages and vigilant wound care. That began to change in 2023, when US regulators approved the first-ever gene therapy for a form of epidermolysis bullosa (EB)—a life-altering disorder that leaves skin so fragile it blisters and tears at the slightest touch. According to Nature.com, the gel-based treatment, called beremagene geperpavec (B-VEC, marketed as Vyjuvek), marked a turning point: instead of merely managing symptoms, it offered true repair.
The Troop family of Utah, with four children living with EB, saw firsthand the transformation gene therapy could bring. After years of stubborn, slow-healing wounds, the children watched their skin heal and grew confident enough to return to activities—from backflips to mountain biking—that once seemed impossible. It was, as their mother KaDee put it, a “big change.”
B-VEC’s approval was historic: the first gene-replacement therapy for a non-cancerous skin disorder, and the first topical gene therapy for any disease that can be applied at home. Developed by Krystal Biotech, B-VEC uses a modified herpes simplex virus to deliver healthy genetic instructions to skin cells, restoring production of a vital collagen protein. Clinical trials showed two-thirds of wounds treated with B-VEC healed completely after six months, compared to less than a quarter with placebo.
This was just the beginning. In 2025, another gene therapy, prademagene zamikeracel (pz-cel, marketed as Zevaskyn), was approved. Delivered as a skin graft, pz-cel also repairs the genetic root of recessive dystrophic EB. Both therapies mark a shift from palliative care to precision medicine, offering lasting wound repair and reducing pain, itchiness, and complications like fused fingers.
Yet, these advances are not cures. The therapies target only the skin, leaving internal symptoms and other complications unaddressed. Cost and access remain significant challenges. Still, for diseases once defined by chronic pain and neglect, these are major steps forward.
The momentum continues. Researchers are developing therapies that inject gene-corrected cells directly into wounds, or harness gene-editing tools like CRISPR for more precise DNA repair. Others are exploring stem cell technologies to create grafts that could cover more of the body or even treat internal tissues, holding promise for broader impact and longer-lasting results. Early successes in treating related disorders, such as ichthyosis and Darier disease, suggest this approach could benefit a wider range of patients.
Despite the hurdles—economic, logistical, and scientific—the progress is undeniable. Gene therapy has shown that fragile skin can be strengthened, and rare conditions need not be left behind. For families like the Troops, the promise is not just theoretical; it is visible in healed skin and reclaimed childhoods. While not a cure, these therapies are a crucial start—paving the way for a future where hope is measured not in bandages, but in possibility.
